Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2019

View Archived Issues

Secretome spills tumors' secrets

Hearing loss gene therapy works in adult mice

Dengue antibodies promote Zika-induced microcephaly

OKYO Pharma and collaborators report in vivo data for OKYO-0101 in dry eye murine model

Inflazome patents new NLRP3 inflammasome inhibitors

Boehringer Ingelheim presents promising data from proof-of-concept trial of BI-655130

AbbVie presents Mcl-1 inhibitors

Shanghai Ennova Biopharmaceutical identifies PD-1/PD-L1 interaction inhibitors

Allergan presents phase I/II results for bimatoprost sustained-release implants

Novel gene therapy prevents the onset of retinal degeneration in vivo

University of Toledo describes new HDAC inhibitors

Patient enrollment ongoing in phase II study of VRP-HER2 vaccine plus pembrolizumab

Promising interim data reported from first cohort of SUNRISE-PD study of AXO-Lenti-PD

ACADIA Pharmaceuticals divulges 5-HT2A receptor ligands

Extended evaluation phase findings from SONICS study of Recorlev in endogenous Cushing's syndrome

Characterization of novel negative allosteric modulators of metabotropic glutamate mGlu5 receptor

Steroidogenic 17beta-HSD2 inhibition for targeted intracrine therapy in bone fracture healing

Phase II results of TOL-463 for the treatment of bacterial vaginosis and vulvovaginal candidiasis

Mutations in TONSL, a fundamental DNA repair protein, cause SPONASTRIME dysplasia

Phase IIb FLUTE study of APT-1011 in eosinophilic esophagitis meets primary endpoint

Bridge Medicines signs agreement with Weill Cornell Medicine to develop novel S1P receptor modulator

CKAP4 unveiled as a new therapeutic target for PDAC

Phase III trials of vadadustat in Japanese patients with anemia due to CKD meet primary endpoint

Seres and AstraZeneca collaborate to study use of microbiome therapeutics in immuno-oncology

Axovant reports 3-month data on patient with infantile Tay-Sachs disease treated with AXO-AAV-GM2

FDA approves Dupixent for use in adolescents with moderate to severe atopic dermatitis

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema
BioWorld
Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...